Mirae Asset Securities named lead manager…에볼루션 바카라사이트 aimed at securities report submission within the year

[by Kang, In Hyo] AimedBio, a company specializing in the development of antibody-drug conjugates (ADCs), announced on June 25 that it has successfully passed the technology evaluation required for listing on the technology-specialized market.
에볼루션 바카라사이트 demonstrated its technological excellence and strong business potential by receiving A and A grades from two Korea Exchange-designated technology evaluation agencies. With this achievement, the company has fulfilled the main requirements for a technology-specialized listing and plans to initiate full-scale preparations for listing on the KOSDAQ market in H2 2025. Mirae Asset Securities is serving as the lead manager, and 에볼루션 바카라사이트 intends to submit a securities registration statement within the year.
에볼루션 바카라사이트 has established a differentiated ADC pipeline by integrating new target discovery, antibody development, intermediary research technologies, and its proprietary linker-payload platform, all centered on addressing unmet medical needs. Leveraging these integrated R&D capabilities, the company successfully signed a technology transfer agreement last year with U.S.-based Biohaven for ‘AMB302 (development code).’ More recently, 에볼루션 바카라사이트 further demonstrated its technological competitiveness by entering into co-development and licensing agreements with SK Plasma for AMB303.
In addition, 에볼루션 바카라사이트 successfully completed its pre-IPO (pre-listing investment) round ahead of schedule, securing a total investment of KRW 51.1 billion (approximately USD 37.7 million) from major Korean institutional investors, reflecting the market’s strong expectations in the company’s potential.
“This technology evaluation is the result of officially recognizing our technological perfection and global commercialization capabilities,” stated Her Nam-gu, CEO of 에볼루션 바카라사이트. “We will leverage the momentum gained through the listing process to accelerate our growth and leap forward as a global biotechnology company at the forefront of innovative anticancer drug development.”